← Evidence map

ArticleNeuro-oncology2023

Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.

Vincenzo Di Nunno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. | OpenQuestion